Efficacy, effectiveness and safety of Comirnaty vaccine in the prevention of symptomatic and asymptomatic SARS-CoV-2 infections

The high infectiousness and contagiousness of the SARS-CoV-2, as well as the alarmingly severe course of COVID-19, inspired research teams from around the world to begin an urgent search for effective methods to neutralize the new pathogen. The mRNA vaccine Comirnaty was the first conditionally licensed vaccine against SARS-CoV-2. Its key ingredient is a fragment of matrix RNA obtained by in vitro transcription that corresponds to the sequence that encodes the spike protein (S protein) of the SARSCoV-2. Today, it is well established that in the face of the continued evolution of the SARS-CoV-2, the effectiveness of the vacci-nation in the core regimen is not sufficient to prevent infection. However, the sustained high level of vaccine protection against severe forms of COVID-19 can significantly reduce hospitalizations and deaths. In addition, the documented risk of serious adverse events following each dose of the vaccine appears relatively small compared to the potential health consequences of COVID-19 infection. This article presents scientific studies describing the role of the Comirnaty vaccine in the prevention of COVID-19 infection and severity.